Client Work

Debiopharm Innovation Fund and Benchstrength co-lead a C$7.9 million seed funding round for Altis Labs Inc.

Reading Time 1 minute read

Overview

Client

Debiopharm Innovation Fund

Closed June 2023

On June 22, 2023, Altis Labs Inc., a computational imaging company accelerating clinical trials with artificial intelligence, announced the closing of its C$7.9 million seed funding round co-led by Debiopharm Innovation Fund and Benchstrength.

Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, provides funding and guidance for companies with an ambition to improve the patient journey and transform pharmaceutical research and development.

Fasken advised Debiopharm Innovation Fund with a team led Will Shaw and Sylvie Bourdeau, including Alec McIlwraith-Black, Hashim Ghazi, Chris Dittrich, and Laura Fetter.

Jurisdiction

Ontario

Team

Will Shaw, Partner | Co-leader, Technology, Media and Telecommunications and Co-leader, Emerging Technology, Toronto, ON, +1 416 865 4554, wshaw@fasken.com
Sylvie Bourdeau, Partner, Montréal, QC, +1 514 397 4388, sbourdeau@fasken.com
Alec McIlwraith-Black, Associate, Toronto, ON, +1 416 868 3468, amcIlwraith-black@fasken.com
Hashim Ghazi , Counsel, Toronto, ON, +1 416 868 3472, hghazi@fasken.com
Chris Dittrich, Partner, Toronto, ON, +1 416 868 3363, cdittrich@fasken.com
Laura Fetter, Counsel, Toronto, ON, +1 416 865 4450, lfetter@fasken.com